Rybelsus

News

white pills spilling out of a pill bottle

Lilly weakens on data reveal for oral obesity candidate

Eli Lilly is preparing to file for approval of its oral weight-loss drug orforglipron before year-end, but not all are convinced by the data.

News

Novo's oral GLP-1 is first to claim heart health label

Novo Nordisk's Rybelsus has become the first oral GLP-1 agonist to pick up a regulatory approval for cardiovascular risk reduction.

News

Novo Nordisk obesity drug linked to rare cause of sight loss

The EMA has become the first regulator to link the use of Novo Nordisk's GLP-1 agonist semaglutide with sight-robbing disorder NAION.

News

ACC25: Ozempic shows its value in PAD

Novo Nordisk's Ozempic has been shown to improve walking distance in people with diabetes and peripheral artery disease in the STRIDE trial.

News

Geron finally brings a drug to market as FDA clears Rytelo

More than 30 years after it was first founded, Geron has claimed FDA approval for its first product – myelodysplastic syndromes (MDS) treatment Rytelo.

Market Access

Weighing the pros and cons, and dollars and cents, of the ne...

Obesity rates in the United States have tripled since the 1980s. According to the CDC, a mind-boggling 41.9% of adults were obese as of 2020.

Lilly weakens on data reveal for oral obesity candidate

Novo's oral GLP-1 is first to claim heart health label

Novo Nordisk obesity drug linked to rare cause of sight loss

ACC25: Ozempic shows its value in PAD

Geron finally brings a drug to market as FDA clears Rytelo

Weighing the pros and cons, and dollars and cents, of the ne...

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

Rybelsus

Editor's Picks